미분류

[STOCK WATCH] CHA Biotech closes with no changes

By 최희석
  • Published : Sept 20, 2016 - 15:37
  • Updated : Sept 20, 2016 - 15:37

[THE INVESTOR] On Sept. 20, CHA Biotech (085660) closed at 15,300 won (US$13.65), unchanged from Sept. 19 close. It had declined 8.55% through the past month. Standard deviation, the risk index for stock price, was 1.9% on the same period of time over one month.


  
- The Return On Risk, -4.4, is in the lower class, it is lower than the industrial index
- Most related stocks have also increased. Pharmacy industry +1.4%
- Target price KRW 22,000, has 41% disparate to increase compared with stock price.
- Institutions and Foreigners sell, Individuals buy
- Turnover Rate and Price Range both proper
- The main shareholding group is Individuals


Compared with its close competitors within the same industry, KOSDAQ, since the monthly volatility of CHA Biotech was at a low level, the earnings rate over one month was also relatively lower than that of its peer group. Over the recent month, the return-on-risk, the return on investment with consideration about risk, was -4.4%. As bearish stock price trend, the return-on-risk was poor, compared with its peer group. Moreover, compared with the KOSDAQ industry, the return-on-risk is below the industrial mean, -3.8, and thus it is hard to say that the industrial comparison performance was positive.

As of Sept. 19, institutions have been selling for the past three trading days and foreigners have been selling for the past two trading days. As a shareholding sum by investor group for the past four weeks, foreigners have sold 29,878 shares and institutions have sold 16,802 shares with a changing stance to selling from buying. However, during the same period, individuals have bought 46,680 shares lessening its position.


Cumulated shareholdings per investor group (1Mo) Total shareholdings per investor group
 


By HeRo (hero@heraldcorp.com)

This article is produced by the algorithm developed by the artificial intelligence developer ThinkPool in collaboration with Herald Corp.